丙型肝炎全病程管理模式的有益构建与应用

doi:10.19871/j.cnki.xfcrbzz.2025.01.014

摘要/Abstract

摘要： 目的本文旨在通过介绍沈阳市第六人民医院丙型肝炎全病程管理的现状、目的、方法和成果,探索丙型肝炎管理的新模式,为临床实践提供参考依据。方法按照“丙型肝炎全病程管理模式”,全院应筛尽筛,抗HCV抗体阳性者鼓励检查HCV RNA,确诊病例由授权医师负责治疗方案选择、按时随访,并将筛查、治疗、随访信息录入“中国疾病预防控制信息系统丙型肝炎防治信息系统”。根据治疗率、随访率、持续病毒学应答（sustained virological response,SVR）率等对比评估“全病程管理模式”的先进性、可行性。结果沈阳市第六人民医院在开展丙型肝炎全病程管理的1年里,通过不断优化工作流程,提高了丙型肝炎的新发现率、诊断率和治疗率,实现了数据的可统计。实施后,新发丙型肝炎病例数较实施前增加84%;就诊患者HCV RNA检测率100%,治疗率83.26%;治疗后随访患者中,快速病毒学应答（rapid virological response,RVR）率达97.67%,早期病毒学应答（early virological response,EVR）率达83.46%,SVR率达90.48%。实现了丙型肝炎诊疗数据的量化,填补了本院既往数据管理空白,为今后的丙型肝炎全病程管理工作提升奠定基础。结论通过加强丙型肝炎全病程管理中的组织管理、筛查、随访管理环节,提高患者的治疗依从性,提升诊断率与治愈率,减弱新发感染风险与病死风险。

关键词: 丙型肝炎, 全病程管理, 治疗依从性, 诊断率, 治愈率

Abstract: Objective This article explores a new hepatitis C management model by presenting the current status, Objectives, methods, and outcomes of full-course management at Shenyang Sixth People's Hospital, offering a reference for clinical practice. Method According to the "HCV full-course management model", the HCV high-risk group should receive regular screening, and Anti-HCV positive patients were recommended to undergo HCV RNA tests. Authorized physicians determine therapeutic regimen, follow up HCV infected patients, and enter screening, treatment, and follow-up information into "HCV Prevention and Control Information System of the Chinese Center for Disease Control and Prevention Information System". The advancement and feasibility of the "full-course management model" were evaluated and compared based on treatment rate, follow-up rate, the sustained virological response (SVR) rate, etc. Result During the one-year implementation of the whole-course management of hepatitis C in our hospital, through continuous optimization of the work process, the new discovery rate, diagnosis rate and treatment rate of hepatitis C have been increased, and the data has become statistically available. After the implementation, the number of newly diagnosed hepatitis C patients increased by 84% compared with that before the implementation, the HCV RNA detection rate of the patients was 100%, and the treatment rate was 83.26%, among the patients followed up after treatment, the rapid virological response (RVR) rate reached 97.67%. The early virological response (EVR) rate reached 83.46%, the SVR rate reached 90.48%. The quantification of hepatitis C diagnosis and treatment data has been realized, filling the gap in previous data management of our hospital and laying a foundation for the improvement of the whole-course management of hepatitis C in the future. Conclusion By strengthening the organizational management, screening, and follow-up management aspects of the full-course management of hepatitis C, patient treatment adherence was improved, leading to an increase in diagnosis and cure rates, and a reduction in the risk of new infections and mortality.

Key words: Hepatitis C, Total course management, Treatment compliance, Diagnosis rate, Cure rate

中图分类号:

R197.1

孙胜男, 梁煊, 赵蕊. 丙型肝炎全病程管理模式的有益构建与应用[J]. 新发传染病电子杂志, 2025, 10(1): 73-76.

Sun Shengnan, Liang Xuan,Zhao Rui. The beneficial construction and application of the whole-course management model for hepatitis C[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(1): 73-76.

参考文献

[1] WORLD HEALTH ORGANIZATION.Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[M].Geneva: World Health Organization, 2022.
[2] COPPOLA N, ALESSIO L, ONORAT O, et al.Epidemiology and Management of Hepatitis C Virus Infections in Immigrant Populations[J].Infect Dis Poverty, 2019, 8(1):17.
[3] WARKAD SD, SONG KS, PAL D, et al.Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies[J].Sensors(Basel), 2019, 19(19):4257.
[4] WESTBROOK RH AND DUSHEIKO G.Natural history of hepatis C[J].J Hepatol, 2014, 61(Suppl 1):58-68.
[5] TOWNSHEND-BULSON L, ROIK E, BARBOUR Y, et al.The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals[J].PLoS One, 2021, 16(12): e0260970.
[6] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019版)[J].临床肝胆病杂志, 2019, 35(12): 2670-2686.
[7] 丁国伟, 庞琳, 王晓春, 等. 2017-2019年哨点医院丙型肝炎基线特征及治疗现况分析[J].中华肝脏病杂志, 2020, 28(10): 844-849.
[8] WORLD HEALTH ORGANIZATION. Global health sector strategy on viral hepatitis2016-2021[R].Geneva:World Health Organization.
[9] 陈雨欣, 吴超. 医院内丙型肝炎筛查和转诊路径的建立与实施[J].中华肝脏病杂志, 2020, 28(10): 820-823.
[10] 王飞, 卢岩, 张成普. 丙肝筛查与管理信息化平台的建设与应用研究[J].现代医院管理, 2018, 16(1): 79-80,86.
[11] 黄睿, 饶慧瑛.“消除”背景下的丙型肝炎病毒感染现状及筛查、诊断对策[J].诊断学理论与实践, 2024, 23(1): 1-8.
[12] 陆彦盟, 李仕雄, 向文耀, 等. 医院丙肝微消除模式的建立与应用成效[J].现代医院, 2024, 24(4): 651-653.
[13] 中联肝健康促进中心, 中华医学会肝病学分会, 中华医学会检验医学分会, 等. 中国丙型病毒性肝炎院内筛查管理流程(试行)[J].中华肝脏病杂志, 2021, 29(4): 319-325.
[14] 戚艳波, 贾豫晨. 2019年云南省法定传染病漏报与报卡质量分析[J].现代预防医学, 2021, 48(8):1511-1514.
[15] GHANY MG,MORGAN TR, AASLD-IDSA HEPATITIS C GUIDANCE PANEL. Hepatitis C guidance 2019 update: American As sociation for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for testing,managing,and treating hepatitis C virus infection[J].Hepatology, 2020, 71(2): 686-721.
[16] 陈海新. 细节管理和风险管理在血站质量管理体系中的应用分析[J].当代医学, 2020, 26(1): 114-116.
[17] CHILLIE S, WESTER C, OSBORNE M, et al.CDC recommen-dations for hepatitis C screening among adults: United States, 2020[J].MMWR Recomm Rep, 2020, 69(2): 1-17.
[18] 常宇琨, 章志丹.《丙型肝炎防治指南(2022版)》更新解读[J/CD].新发传染病电子杂志, 2023, 8(6): 89-92.
[19] 李娜娜,张永栋. 丙型肝炎病毒基因分型的相关研究进展[J].临床医学进展, 2023, 13(5): 7598-7603.
[20] 王焱, 韩军, 杨美蓉. 三种DAAs方案治疗慢性丙型肝炎患者两年随访研究[J].实用肝脏病杂志, 2024, 27(1): 32-35.